From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma
about
Immune Modulation in Hematologic MalignanciesRate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathwayLycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma.In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
P2860
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma
@en
type
label
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma
@en
prefLabel
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma
@en
P2860
P1433
P1476
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma
@en
P2093
Jonathan D Licht
P2860
P356
10.1016/J.CCR.2013.12.019
P577
2014-01-01T00:00:00Z